Skip to main content
. 2022 Jan 11;13:245. doi: 10.1038/s41467-021-27921-1

Fig. 6. AKT inhibition blocks MAPK4 tumor-promoting activity in TNBC.

Fig. 6

Proliferation assays on the engineered a HCC1395, b HCC1806, and c SUM159 cells with 0.5 µg/ml Dox-induced expression of MAPK4 (iMAPK4) or control (iCtrl). The cells were also treated with 1 µM of the AKT inhibitors MK2206 (left) or GSK2141795 (right) or control. Data are mean ± SD. d Representative images and quantification of soft-agar assays on Dox-induced SUM159-iMAPK4 cells treated with AKT inhibitors MK2206, GSK2141795, GDC-0068, and DMSO control. Also shown are the control-treated SUM159-iMAPK4 cells without Dox induction. Bar: 500 μm. Data are mean ± SEM. P value by unpaired two-tailed Student’s t test. Data are representative of at least 3 independent experiments. Source data are provided as a Source data file.